Showing results (331-340 of 345) with videos related to

Sort By:
Pageof 35
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Differential diagnosis of suspected multiple sclerosis: a consensus approachD H Miller, B G Weinshenker, M Filippi, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 14, 2001
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous managementE J Dippel, D J Kereiakes, D A Tramuta, et al.
American Heart Journal|February 22, 2003
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary interventionMark I Furman, Dean J Kereiakes, Lori A Krueger, et al.
Neurology|November 26, 2003
Contrast letter acuity as a visual component for the Multiple Sclerosis Functional CompositeL J Balcer, M L Baier, J A Cohen, et al.
Neurology|September 1, 2007
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELP A Calabresi, G Giovannoni, C Confavreux, et al.
American Heart Journal|October 31, 2001
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximabM I Furman, D J Kereiakes, L A Krueger, et al.
Neurology|April 18, 2007
Natalizumab reduces visual loss in patients with relapsing multiple sclerosisL J Balcer, S L Galetta, P A Calabresi, et al.
Circulation|September 30, 1998
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trialD J Kereiakes, N S Kleiman, J J Ferguson, et al.
American Heart Journal|September 30, 2000
Abciximab provides cost-effective survival advantage in high-volume interventional practiceD J Kereiakes, R L Obenchain, B L Barber, et al.
Nature Communications|June 11, 2026
Influenza coinfection inhibits control of mycobacterial infection in a human challenge modelClaire M Broderick, Oliver Powell, Sam Nichols, et al.
Pageof 35